Rachelle Suzanne Jacques

Board Director

Director

uniQure N.V.Akari Therapeutics Plc Corbus Pharmaceuticals Holdings, Inc.uniQure N.V.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 1 saleJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (3 ops.)

€44k

Latest filing published 21 May 2026 for Corbus Pharmaceuticals Holdings, Inc.. Read the official filing

Filing timeline

BuySale

Rachelle Suzanne Jacques

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Rachelle Suzanne Jacques: trading record in brief

This profile gathers the share dealings of Rachelle Suzanne Jacques across 3 companies, led by uniQure N.V., Corbus Pharmaceuticals Holdings, Inc. and Akari Therapeutics Plc. In total, 12 filings cover trades dated from 24 February 2022 to 19 May 2026.

On the market, this insider has only sold: 3 sales, €44k in total. Other entries cover 9 share grants.

On 21 May 2026 came the latest disclosure, a share grant in Corbus Pharmaceuticals Holdings, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.